Mucinex Childrens

Description

Mucinex® Children's Cough is a liquid formulation designed for pediatric use, containing Dextromethorphan HBr as a cough suppressant at a concentration of 5 mg per 5 mL and Guaifenesin as an expectorant at a concentration of 100 mg per 5 mL. The product is presented in a cherry-flavored liquid form, packaged in a 4 fluid ounce (118 mL) bottle.

Uses and Indications

This drug is indicated for the relief of cough associated with minor throat and bronchial irritation, which may occur due to the common cold or inhaled irritants. It assists in loosening phlegm (mucus) and thinning bronchial secretions, thereby facilitating the clearance of mucus from the bronchial passageways and making coughs more productive.

Additionally, this drug temporarily alleviates the intensity of coughing and reduces the impulse to cough, which may help children achieve restful sleep.

No teratogenic or nonteratogenic effects have been reported.

Dosage and Administration

The maximum recommended dosage is six doses within a 24-hour period. Dosing should be measured exclusively with the dosing cup provided with the product; the use of this cup with other products is not advised.

For children aged 6 years to under 12 years, the recommended dose is 5 mL to 10 mL administered every 4 hours as needed. For children aged 4 years to under 6 years, the appropriate dose is 2.5 mL to 5 mL every 4 hours as needed. It is important to note that this product is not recommended for use in children under 4 years of age.

Healthcare professionals should ensure that dosing adheres strictly to these guidelines or as directed by a physician.

Contraindications

Use of this product is contraindicated in children who are currently taking a prescription monoamine oxidase inhibitor (MAOI) or within 2 weeks of discontinuing an MAOI. MAOIs are typically prescribed for depression, psychiatric or emotional conditions, or Parkinson's disease. If there is uncertainty regarding the presence of an MAOI in a child's prescription medication, consultation with a healthcare professional is advised prior to administration of this product. Additionally, it is contraindicated to exceed the recommended dosage while using this product.

Warnings and Precautions

The use of this product is contraindicated in children who are currently taking a prescription monoamine oxidase inhibitor (MAOI) or have taken one within the past two weeks. MAOIs are commonly prescribed for depression, psychiatric or emotional conditions, and Parkinson's disease. If there is uncertainty regarding whether a child's prescription includes an MAOI, it is imperative to consult a healthcare professional, such as a doctor or pharmacist, prior to administration.

Healthcare professionals should advise caregivers to seek medical guidance before using this product if the child presents with a cough accompanied by excessive phlegm (mucus) or if the cough is persistent or chronic, as seen in conditions like asthma.

It is crucial to adhere strictly to the recommended dosage; exceeding the directed amount can lead to adverse effects. Caregivers should be instructed to discontinue use and consult a healthcare provider if the child's cough persists for more than seven days, recurs, or is accompanied by fever, rash, or a persistent headache, as these symptoms may indicate a more serious underlying condition.

To ensure safety, this product must be kept out of reach of children. In the event of an overdose, immediate medical assistance should be sought, or contact with a Poison Control Center is advised.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this medication. Serious warnings include the contraindication of use in children who are currently taking a prescription monoamine oxidase inhibitor (MAOI) or within 2 weeks of discontinuing such medication, as this could lead to significant health risks.

Before administering this medication to a child, it is advisable to consult a healthcare professional if the child has a cough that is accompanied by excessive phlegm or if the cough is persistent or chronic, such as that which occurs with asthma.

Patients are also advised to discontinue use and seek medical advice if the cough persists for more than 7 days, recurs, or is accompanied by fever, rash, or a persistent headache, as these symptoms may indicate a serious underlying condition.

In the event of an overdose, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended to ensure patient safety.

Drug Interactions

The concomitant use of this product with monoamine oxidase inhibitors (MAOIs) is contraindicated. This includes prescription medications used for the treatment of depression, psychiatric or emotional conditions, and Parkinson's disease. Administration of this product in children who are currently taking an MAOI, or within 2 weeks of discontinuing an MAOI, may lead to serious adverse effects.

Healthcare professionals are advised to confirm whether a child's prescription medication contains an MAOI prior to the administration of this product. If there is any uncertainty, consultation with a doctor or pharmacist is recommended to ensure patient safety.

Packaging & NDC

Below are the non-prescription pack sizes of Mucinex Childrens (dextromethorphan hydrobromide and guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should not use this product if they are currently taking a prescription monoamine oxidase inhibitor (MAOI) or within 2 weeks of stopping an MAOI. Prior to use, it is advisable to consult a healthcare professional if the child has a cough associated with excessive phlegm or a persistent cough, such as that which occurs with asthma.

When administering this product, it is crucial to adhere to the recommended dosing guidelines. The maximum dosage should not exceed 6 doses within a 24-hour period. The dosing cup provided should be used exclusively for this product, and not with any other medications. The recommended dosages are as follows: for children aged 6 years to under 12 years, 5 mL to 10 mL every 4 hours; for children aged 4 years to under 6 years, 2.5 mL to 5 mL every 4 hours. This product is not indicated for children under 4 years of age.

Parents and caregivers should monitor the child closely and discontinue use if the cough persists for more than 7 days, recurs, or is accompanied by fever, rash, or a persistent headache. It is essential to keep this product out of reach of children, and in the event of an overdose, medical assistance or contact with a Poison Control Center should be sought immediately.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

The safety of Mucinex® Children's Cough during pregnancy has not been established. Pregnant patients or those planning to become pregnant should consult a healthcare professional prior to use, as there may be potential risks to the fetus; however, specific studies or data regarding these risks are not provided in the prescribing information. No specific dosage modifications for pregnant individuals are mentioned. It is strongly advised that medical advice be sought before using this product during pregnancy to ensure the safety of both the patient and the developing fetus.

Lactation

There are no specific warnings or recommendations regarding nursing mothers or lactation in the provided text. Therefore, healthcare professionals should consider the absence of data when advising lactating mothers about the use of this medication. It is advisable to monitor breastfed infants for any potential effects, although no specific concerns have been identified in the available information.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdose, it is imperative to seek immediate medical assistance or contact a Poison Control Center without delay. Prompt intervention is crucial to mitigate potential adverse effects associated with the overdose.

Healthcare professionals should be aware that the symptoms of overdose may vary depending on the specific substance involved. Therefore, a thorough assessment of the patient's condition is essential to determine the appropriate course of action.

Management of an overdose typically involves supportive care and symptomatic treatment. This may include monitoring vital signs, providing respiratory support, and administering activated charcoal if indicated and within the appropriate time frame. In cases where specific antidotes are available, their use should be considered based on the clinical scenario.

It is essential for healthcare providers to remain vigilant and prepared to implement emergency protocols in the event of an overdose, ensuring the safety and well-being of the patient.

Nonclinical Toxicology

No information is available regarding teratogenic or non-teratogenic effects. Additionally, there is no data provided concerning nonclinical toxicology, animal pharmacology, or toxicology.

Postmarketing Experience

Reports of side effects have been received through voluntary submissions and surveillance programs. Patients and healthcare professionals are encouraged to report any adverse events associated with the use of the product to the designated contact number provided for this purpose.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion. In the event of an overdose, patients should be instructed to seek medical help or contact a Poison Control Center immediately.

It is crucial to inform patients that this product should not be used in children who are currently taking a prescription monoamine oxidase inhibitor (MAOI) or within 2 weeks of stopping such medication. Patients should be encouraged to consult with a doctor or pharmacist if they are uncertain whether their child's prescription includes an MAOI.

Patients should be instructed to discontinue use and consult a doctor if a cough persists for more than 7 days, returns, or is accompanied by fever, rash, or a persistent headache, as these symptoms may indicate a serious condition.

While using this product, patients must be reminded not to exceed the recommended dosage. Additionally, healthcare providers should advise patients to seek medical advice before use if the child has a cough that produces excessive phlegm (mucus) or if the cough is persistent or chronic, such as that associated with asthma.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available upon request. It is essential to store the product at a temperature range of 20-25°C (68-77°F). Refrigeration is not recommended, as the product should not be exposed to temperatures outside this specified range. Proper handling and storage conditions are crucial to maintain the integrity and efficacy of the product.

Additional Clinical Information

The medication is administered orally. Clinicians should advise patients to keep the medication out of reach of children. In the event of an overdose, patients are instructed to seek medical assistance or contact a Poison Control Center immediately. No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Mucinex Childrens, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)